Skip to main content
. Author manuscript; available in PMC: 2012 Mar 1.
Published in final edited form as: Behav Brain Res. 2011 Mar 1;217(2):399–407. doi: 10.1016/j.bbr.2010.11.018

Figure 2. The systemic MEK inhibitor SL327 was unable to impair extinction of EtOH-CPP.

Figure 2

(A) All groups showed significant preference for the EtOH-paired floor following acquisition (Test 1). Administration of 30 mg/kg SL327 (SL-30) or 50 mg/kg SL327 (SL-50) 30-min before extinction trials did not impair normal extinction as seen in the Vehicle group (Test 2). The SL-50 group showed a significant place aversion following extinction. (B) All groups showed a decrease in activity over the course of extinction trials in Experiment 2. Pre-treatment with SL327 did not significantly reduce extinction activity as compared to the Vehicle group. Error bars indicate standard error of the mean. A total of 24 subjects (25%) were removed because of failure to express >50% preference on Test 1. An additional two subjects were removed because of procedural errors.

* denotes a significant decrease in preference on Test 2 compared to Test 1 (p < .05).

# denotes a significant difference in preference from Vehicle group on Test 2 (p < .05).